Haier TV Has Been Awarded the EU Accessibility Act Certificate by DEKRA -- Marking the First Certificate of its Kind in the TV Industry
In Europe, 'accessibility' is no longer merely an extension of social responsibility, but a legal requirement for product design. Under the European Accessibility Act (EAA) (EU) 2019/882, from 2025 onward, ICT products and services entering the EU market must meet specific accessibility requirements to ensure that elderly users and those with visual, hearing, or other impairments can access technology equally, safely, and without barriers.
The certificate confirms that the Haier TV products meet EAA accessibility technical standards for audiovisual products across multiple critical dimensions, including visual display, subtitles, audio output, menu navigation, and remote-control usability. This means users with hearing impairments can 'see' sound through captions, and those with visual impairments can 'hear' what's on screen. Haier TV bridges sensory barriers and delivers a more inclusive viewing experience.
'This certificate is a testament to Haier TV's enduring dedication to making technology accessible to everyone,' said Junguang Liu, Vice President of Haier Smart Home and General Manager of Audio-Visual BU. 'We will keep pushing the boundaries to discover new ways in which technology can deliver greater equality, inclusivity, and happiness to every household.'
DEKRA, as the independent third-party testing, inspection, and certification organization, conducted the evaluation based on EAADIRECTIVE 2019/882/EU, EN 301549 V3.2.1, and Draft EN 301 549 V4.1.1c (2025-05) V.0.0.15, enabling companies to identify compliance paths and validate design implementations, ensuring that accessibility requirements are translated from regulation into reality.
From millisecond-level voice command responses to adaptive subtitle rendering, from precise spatial audio positioning to a streamlined user interface — every technical detail embodies Haier TV's commitment to equal access. This certificate reflects Haier TV's dedication to user-centered innovation, driven by world-class R&D. As a global benchmark, Haier TV continues to advance technology for accessibility and inclusivity.
View original content to download multimedia: https://www.prnewswire.com/news-releases/haier-tv-has-been-awarded-the-eu-accessibility-act-certificate-by-dekra--marking-the-first-certificate-of-its-kind-in-the-tv-industry-302507811.html
SOURCE Haier Smart Home
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
G-Shock Reworked Its Original Watch Using a 1,200-Year-Old Japanese Craft
The toughest name in time just found a new way to showcase its signature shock resistance. Every product is carefully selected by our editors. If you buy from a link, we may earn a commission. Learn more G-Shock's new watch may revisit its oldest design from the 1980s. But the technique used for its unique bezel and bracelet actually dates back more than a millennium. Tsuiki, believed to have originated in the Heian period (794 to 1185 AD), refers to the Japanese craft of hammering sheets of metal into three-dimensional objects. Over the years, it's been used to shape armor, cookware and, now, digital watches, with G-Shock's 5000 series serving as the latest canvas to showcase tsuiki's stunning, handmade effect. Hammer time As the name implies, the brand-new MRG-B5000HT slots into the brand's catalog by way of the MR-G luxury sub-division. Yet even by those lofty standards, the watch standard apart as a one-of-a-kind offering from the toughest name in timekeeping. According to G-Shock, only 500 examples will be available worldwide, each one hand-hammered by master artisan Kazuya Watanabe — a nod to G-Shock's signature shock resistance. Both the bezel and bracelet are made from DAT55G, a titanium alloy that G-Shock claims is three times harder than pure titanium, and colored with a DLC coating designed to mimic traditional sword design. Otherwise, in true G-Shock fashion, the watch features Tough Solar power, Multi-Band 6, Bluetooth, sapphire glass, an LED backlight and 200 meters of water resistance. Availability and pricing Already breaking cover overseas, the MRG-B5000HT will cost 935,000 Japanese yen (roughly $6,400) when it releases in August. Casio has yet to confirm US pricing and availability, but, as stated, only 500 examples exist due to the artisanal nature of the watch. G-Shock MRG-B5000HT Learn More Jack Seemer is the executive editor at Gear Patrol, with over a decade of experience in product journalism. He currently reports on a wide range of topics, including footwear, watches, EDC, cookware and more.
Washington Post
an hour ago
- Washington Post
Trump calls leaders of Thailand and Cambodia to push for a ceasefire
President Donald Trump said Saturday that he had called the leaders of Cambodia and Thailand to urge them to reach a ceasefire, suggesting that if their deadly border conflict continues, he would hit both countries with heavy tariffs on Aug. 1. The three-day-long clash between the two countries has been escalating, with more than 30 dead, thousands displaced and troops massing on both sides of the border, prompting growing concern from global leaders. Each country blames the other for starting the conflict and says it is acting in self defense. Trump said on Truth Social that he had spoken with both Cambodian Prime Minister Hun Manet and Phumtham Wechayachai, Thailand's acting leader, to urge an end to the skirmish. The United States is engaged in trade talks with Thailand and Cambodia, he noted, but he could cease those negotiations. 'We happen to be, by coincidence, currently dealing on Trade with both Countries, but do not want to make any Deal, with either Country, if they are fighting — And I have told them so!' Trump posted. In a separate post, he said he had a 'good conversation' with the Thai leader. 'After speaking to both Parties, Ceasefire, Peace, and Prosperity seems to be a natural. We will soon see!' he wrote. He also suggested that his administration was adept at handling international conflicts. 'I am trying to simplify a complex situation! Many people are being killed in this War, but it very much reminds me of the Conflict between Pakistan and India, which was brought to a successful halt,' he added. Trump's mention of India and Pakistan referred to a U.S.-brokered ceasefire between those two countries that was reached in early May after several days of heavy fighting broke out. That ceasefire was reached after Secretary of State Marco Rubio engaged in intensive shuttle diplomacy between Indian and Pakistani leaders. The president's latest pronouncements were another reflection of the way he is wielding the threat of tariffs to push other nations to bend to his preferences on issues beyond trade. Imports from Thailand and Cambodia are slated to face among the Trump administration's heaviest levies, 36 percent, if the countries do not reach a trade deal with the U.S. by Aug. 1. Trump made his announcement Saturday while visiting Scotland to play golf at his course in Turnberry, a trip that has attracted both supporters and protesters. His public intervention in the Thailand-Cambodia conflict raises pressure on the two countries, but the outcome is far from clear. Cambodia called for an 'immediate ceasefire' on Friday. But Thai officials have tempered their response. Thailand 'agrees in principle to have a ceasefire in place,' Phumtham, the acting Thai prime minister, posted on Facebook on Saturday after Trump's announcement. 'However, Thailand would like to see sincere intention from the Cambodian side.' Thai Foreign Minister Maris Sangiampongsa also said Saturday that Cambodia must be the first to suspend hostilities since Thailand accuses Cambodia of initiating the conflict. Sangiampongsa earlier turned down the prospect of third-party mediation, saying that negotiations must be bilateral. In three days of fighting, the clashes have killed at least 33 people. Thirteen Cambodians and 20 Thais have died, according to the Associated Press, and most of those killed have been civilians. The conflict has caused wide disruption in the area, and more than 168,000 people living near the border have been displaced. Cambodian Information Minister Neth Pheaktra said Saturday that 37,635 Cambodians were forced to relocate. About 131,000 people on the Thai side have also fled their homes, and Thailand has declared martial law in eight border districts.
Yahoo
2 hours ago
- Yahoo
Pharma sector outlook as Trump's drug tariff deadline looms
Pharmaceutical stocks are in focus as President Trump's drug tariff deadline looms. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Josh Lipton to discuss the impact that pharmaceutical tariffs could have on the sector, Astrazeneca's (AZN) $50 billion commitment to US investments, and how the industry is navigating pressure from Washington and shifting global demand. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Pharmaceutical stocks in focus as we approach President Trump's looming drug tariff deadline. For more, I want to bring in Yahoo Finance senior health reporter Angelique Chenge. That's right, Josh. With that looming deadline, potentially August 1st, for up to 200% in tariffs, we don't know what that number will actually end up being. We've heard from several companies that have announced manufacturing commitments in hopes to thwart that effort. That includes AstraZeneca. We spoke to CEO Pascal Soriot about that, and he did mention that the announcement for $50 billion, that's in addition to $3.5 billion last year, is in part a response to Trump's tariffs. We know others like Eli Lilly and Johnson & Johnson have also announced similarly big announcements of commitments for manufacturing. And this is in play at a time where the industry is also going through a bit of tumult. We know that there is a lot of investment in one of Trump's least favorite countries, that is China. That is the reason why there has been a lot of tension in the biotech world. We also know that big pharma has been pivoting and investing there as well. Licensing deals and the like are on the rise as they look to sort of respond to all the different countries that are looking for what has now been termed health sovereignty. And this plays into that. So, when I asked Pascal about that, about China and the deal making there, here's what he had to say about it. We believe that it's our ethical responsibility to bring medicines to as many people as possible. Of course, there are limitations to what we can do, but we work very hard to do this. And we are lucky enough or good enough or both, that we are growing. And growth brings opportunities. And because we are growing, we are able to invest in United States for the United States, we're able to invest in China for China, and we're also able to seek innovation where it happens. Because actually, if innovation happens in China or in Europe, we need to take this innovation, develop it, and bring it to patients for instance in the United States, but manufacture the product in the United States. Um, and I think that brings me to an important point that people don't talk enough about is that today innovation in our industry takes place in the U.S. U.S. is the biggest innovator for biopharmaceuticals. And it's really important that everything is done to protect that innovation. It's a fantastic engine to bring new medicines to patients but also create good jobs, well-paid jobs, and economic growth. So, as you can hear, a lot of focus on that, on economic growth being the driver as well and needing to respond to these countries and their efforts. AstraZeneca also talked about how it would help shift revenues for the portfolio with a greater reliance on the U.S. Currently, 42% of revenues comes from the U.S. And with this increase in manufacturing, it would be 50%. And that includes GLP-1s. We know that there's a lot of global demand for that drug and for those types of drugs. AstraZeneca has been pursuing an oral form or pill form, which is largely seen as the next frontier in this space. AstraZeneca looking at being able to then supply the rest of the world from the U.S., making it a larger exporter. So, here's what Pascal said about that. It's also a reason, another reason why we are investing in this very large facility. We have our oral GLP-1. Everybody knows GLP-1 by now. These are agents used to help people manage their weight. We have an oral agent, and we have bet on oral agents because we think they are going to be easier for patients, because they will be cheaper, they'll be more accessible, and we will be able to export them around the world, not only supply America. But we also have other products treating cardiovascular metabolic disease. We have a new agent for hypertension for patients who are not controlled on multi-medicines. We have an oral PCSK9 for the control of cholesterol and many others. Cardiovascular metabolic diseases are the biggest killer in the world today, including in the United States. So, you can see the needs are enormous. This plant will supply products for American patients, so American patients will access products that are American-made. But this plant will also export to the billions of patients around the world who need these medicines. The company really moving that pot of money, you know, globally and looking at where it makes the most sense. Pascal also did tell me that in looking at the different areas of the world where the money can be, you know, invested, China, of course, being one of them. And then if you compare the amount that has been put in there, that is $5.3 billion is one of the latest deals that AstraZeneca has done in China. And if you compare that to the $50 billion, while not on the same level, you can still see it's quite a large number. And that's just one of those deals. So, we're starting to see a little bit of bifurcation in how the global pharmaceutical economy is functioning. Related Videos Uncertainty is 'here to stay': What that means for markets BlackRock's Rick Rieder: I Think Rates Can Come Down Elon Musk's 'master plan': Is Tesla an EV maker or AI play? 'We ask for more data' than FICO: VantageScore CEO Sign in to access your portfolio
